

# Northumbria Research Link

Citation: Hennis, Philip J., Cumpstey, Andrew F., O'Doherty, Alasdair, Fernandez, Bernadette O., Gilbert-Kawai, Edward T., Mitchell, Kay, Moyses, Helen, Cobb, Alexandra, Meale, Paula, Pöhl, Helmut, Mythen, Monty G., Grocott, Michael P. W., Levett, Denny Z. H., Martin, Daniel S., Feelisch, Martin and Xtreme Alps research group, (2022) Dietary Nitrate Supplementation Does Not Alter Exercise Efficiency at High Altitude - Further Results From the Xtreme Alps Study. *Frontiers in Physiology*, 13. p. 827235. ISSN 1664-042X

Published by: Frontiers

URL: <https://doi.org/10.3389/fphys.2022.827235>  
<<https://doi.org/10.3389/fphys.2022.827235>>

This version was downloaded from Northumbria Research Link:  
<http://nrl.northumbria.ac.uk/id/eprint/48215/>

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: <http://nrl.northumbria.ac.uk/policies.html>

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher's website (a subscription may be required.)

# Dietary nitrate supplementation does not alter exercise efficiency at high altitude – further results from the Xtreme Alps study

1 Philip J Hennis<sup>1,2†</sup>, Andrew F Cumpstey<sup>3,4†</sup>, Alasdair F O’Doherty<sup>5</sup>, Bernadette O Fernandez<sup>4,6</sup>  
2 Edward T Gilbert-Kawai<sup>1</sup>, Kay Mitchell<sup>3,4</sup>, Helen Moyses<sup>3</sup>, Alexandra Cobb<sup>1</sup>, Paula Meale<sup>1</sup>,  
3 Helmut Pöhl<sup>7</sup>, Monty G Mythen<sup>1</sup>, Michael P W Grocott<sup>3,4</sup>, Denny Z H Levett<sup>3,4</sup>, Daniel S  
4 Martin<sup>1,8\*††</sup> and Martin Feelisch<sup>3,4,6\*††</sup> and the Xtreme Alps research group.

5

6 1. Centre for Altitude, Space and Extreme Environment (CASE) Medicine, University College  
7 London Hospital NIHR Biomedical Research Centre, Institute of Sport Exercise & Health, London,  
8 UK

9 2. SHAPE Research Group, School of Science and Technology, Nottingham Trent University,  
10 Nottingham NG11 8NS, UK

11 3. Perioperative and Critical Care Theme, NIHR Southampton Biomedical Research Centre,  
12 University Hospital Southampton NHS Foundation Trust, Southampton, UK

13 4. Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of  
14 Medicine, University of Southampton, Southampton, UK

15 5. Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne,  
16 UK.

17 6. Warwick Medical School, Division of Metabolic and Vascular Health, University of Warwick,  
18 Coventry, UK

19 7. AURAPA, Bietigheim-Bissingen, Germany

20 8. Peninsula Medical School, University of Plymouth, Plymouth, UK

21

22 †, †† these authors contributed equally

23 \* **Correspondence:**

24 [daniel.martin@plymouth.ac.uk](mailto:daniel.martin@plymouth.ac.uk) or [m.feelisch@soton.ac.uk](mailto:m.feelisch@soton.ac.uk)

25 **Keywords: Exercise, high altitude, hypoxia, nitric oxide, beetroot, nitrite**

## 26 **Abstract**

27 *Introduction:* Nitrate supplementation in the form of beetroot juice (BRJ) ingestion has been shown to  
28 improve exercise tolerance during acute hypoxia, but its effect on exercise physiology remains  
29 unstudied during sustained terrestrial high altitude exposure. We hypothesised that performing exercise  
30 at high altitude would lower circulating nitrate and nitrite levels and that BRJ ingestion would reverse  
31 this phenomenon while concomitantly improving key determinants of aerobic exercise performance.

32 *Methods:* Twenty seven healthy volunteers (21 male) underwent a series of exercise tests at sea level  
33 (SL, London, 75 m) and again after 5-8 days at high altitude (HA, Capanna Regina Margherita or

34 ‘Margherita Hut’, 4559 m). Using a double-blind protocol, participants were randomised to consume  
35 a beetroot/fruit juice beverage (3 doses per day) with high levels of nitrate (~0.18 mmol/kg/day) or a  
36 nitrate-depleted placebo (~11.5  $\mu$ moles/kg/day) control drink, from 3 days prior to the exercise trials  
37 until completion. Submaximal constant work rate cycle tests were performed to determine exercise  
38 efficiency and a maximal incremental ramp exercise test was undertaken to measure aerobic capacity,  
39 using breath-by-breath pulmonary gas exchange measurements throughout. Concentrations of nitrate,  
40 nitrite and nitrosation products were quantified in plasma samples collected at 5 timepoints during the  
41 constant work rate tests. Linear mixed modelling was used to analyse data.

42 *Results:* At both SL & HA, plasma nitrate concentrations were elevated in the nitrate supplementation  
43 group compared to placebo (P<0.001) but did not change throughout increasing exercise work rate.  
44 Delta exercise efficiency was not altered by altitude exposure (P=0.072) or nitrate supplementation  
45 (P=0.836).  $\dot{V}O_{2peak}$  decreased by 24% at high altitude (P<0.001) and was lower in the nitrate-  
46 supplemented group at both sea level and high altitude compared to placebo (P=0.041). Dietary nitrate  
47 supplementation did not alter other peak exercise variables or oxygen consumption at anaerobic  
48 threshold. Circulating nitrite and S-nitrosothiol levels unexpectedly rose in a few individuals right after  
49 cessation of exercise at high altitude.

50 *Conclusion:* Whilst regularly consumed during an 8 day expedition to terrestrial high altitude, nitrate  
51 supplementation did not alter exercise efficiency and other exercise physiological variables, except  
52 decreasing  $\dot{V}O_{2peak}$ . These results and those of others question the practical utility of BRJ  
53 consumption during prolonged altitude exposure.

54

## 55 **1 Introduction**

56 Increasingly, people are traveling to high altitude and performing physical activity for the purposes of  
57 work, recreation and sport. In doing so, these individuals are exposed to atmospheric hypobaric  
58 hypoxia, which impedes physical and cognitive performance and can cause the onset of high altitude  
59 illness (1,2). Performing exercise under hypoxic conditions further increases arterial hypoxaemia (3),  
60 and may predispose for the development of acute mountain sickness (4). Whilst the mechanisms  
61 responsible for altitude-induced reductions in physical and cognitive performance are not fully  
62 understood, harmful effects of atmospheric hypoxia appear to be related to impaired oxygen transport  
63 and/or utilisation pathways. The deleterious effects of atmospheric hypoxia could be mitigated by  
64 interventions that target mechanisms central to these pathways.

65 Nitric oxide (NO) is an important mediator of human physiological responses to hypoxia, not only  
66 because of its effects on pulmonary and cardiovascular function, erythropoiesis and metabolic  
67 regulation (5–8) but also due to its ability to match energy supply and demand at the cellular level

68 (9). Consistent with these actions, high altitude natives have elevated plasma nitrate and nitrite  
69 concentrations (biomarkers of NO production) when compared to sea level controls (10), and  
70 lowlanders increase plasma concentrations of NO metabolites (nitrate, nitrite) and cyclic guanosine  
71 3', 5'-monophosphate (cGMP) during the acclimatization process (11,12). As such, enhanced NO  
72 production is a universal response to hypoxic stress (13) and may be advantageous for acclimatizing  
73 and exercising at high altitude. A significant part of whole-body NO production occurs via the  
74 enzymatic oxidation of L-arginine by NO synthase (NOS) family of enzymes. An alternative, NOS-  
75 independent, pathway to elevate NO production is thought to be provided by increasing the dietary  
76 intake of nitrate (14). An alternative, NOS-independent mechanism through which NO may be  
77 generated in the body is via the reduction of nitrate. The sequential reduction of nitrate to nitrite and  
78 NO via this so-called non-canonical Nitrate-Nitrite-NO pathway has been proposed to be particularly  
79 active in hypoxic environments (15,16). Increasing intake of dietary nitrate and elevating plasma  
80 nitrate and nitrite levels, with the latter being converted to NO and nitroso species, could have the  
81 potential to alter many physiological outcomes (15). Notable dietary nitrate-induced physiological  
82 changes include reduced resting blood pressure (17) and improved endurance exercise performance  
83 (for reviews see (18–21)). A growing body of evidence, mostly obtained in studies conducted at SL,  
84 suggests that dietary nitrate supplementation, via the consumption of nitrate-rich beetroot or green  
85 leafy vegetables, could improve key physiological determinants of aerobic exercise performance to  
86 enhance hypoxic exercise tolerance.

87 Administration of beetroot juice (BRJ) has been reported to improve hypoxic time trial performance  
88 for running (22), cycling (23), walking (24), and to prolong time to exhaustion during cycling (25–  
89 27) and knee-extension exercise (28). However, in other studies BRJ had no ergogenic effect on  
90 running, cycling, or skiing time trial performance (29–31), nor did it alter time to exhaustion during  
91 cycling, walking and forearm exercise (32–34). Any ergogenic effect of BRJ will occur through its  
92 action on one or more of the four physiological determinants of aerobic exercise performance; i) peak  
93 oxygen consumption ( $\dot{V}O_{2peak}$ ), ii) ventilatory anaerobic threshold (AT), iii) exercise economy, iv)  
94 oxygen uptake kinetics (35). Of these determinants of performance, supplementation with BRJ  
95 during hypoxia has been reported to alter exercise economy (22,23,26,27,31),  $\dot{V}O_{2peak}$ , and oxygen  
96 uptake kinetics (26). The role of BRJ on hypoxic exercise economy is most convincing with  
97 decreases in submaximal  $O_2$  utilization with BRJ compared to a placebo reported for a range of  
98 exercise intensities and modalities (22–24,26,27), although conflicting data exists (25,29,31,34).  
99 These studies support a body of evidence attesting to a BRJ-induced improvement in the efficiency

100 of oxygen use during exercise in normoxia, which has been suggested to occur due to greater  
101 efficiency of ATP resynthesis (i.e. higher mitochondrial P/O ratio) and/or improved muscle  
102 contraction efficiency (for reviews see (21,36)). Hypoxic  $\dot{V}O_{2peak}$  has been shown to be both lower  
103 (26) and unchanged (27,30,31) following BRJ administration, whilst the only study regarding  $\dot{V}O_2$   
104 kinetics reported BRJ to lower Tau (the time taken for oxygen uptake to reach 63% of its final  
105 amplitude following a stepwise increase in work rate) during moderate but not severe intensity  
106 exercise (26). It is noteworthy that all of the aforementioned studies ‘simulated’ high altitude  
107 conditions by acutely exposing participants to normobaric hypoxia. Whilst such studies provide  
108 useful contributions to understanding whether BRJ has the potential to ameliorate reductions in  
109 performance determinants upon acute exposure, their validity to conditions at high altitude  
110 environments (i.e. in hypobaric hypoxia) could be challenged.

111 The distinction between ‘simulated’ hypoxic and terrestrial altitude exposure is likely important  
112 given NO metabolism and physiological acclimation to hypoxia can differ according to whether  
113 hypobaric or normobaric hypoxia is employed (for review see, (37)). Furthermore, none of the  
114 ‘simulated’ altitude studies, using either normobaric or hypobaric hypoxia, have investigated the  
115 efficacy of BRJ on exercise physiological responses during hypoxic exposure of more than a few  
116 hours. Altitude acclimatization is a dynamic process, and thus the impact of BRJ on physiological  
117 responses to very acute hypoxia may not translate when the hypoxic dose is delivered over a number  
118 of days or weeks. The majority of people who contend with hypoxic conditions do so over a  
119 prolonged period of time at terrestrial high altitude; thus, studying the potential ergogenic effect of  
120 BRJ on exercise responses in this setting is required to address whether or not BRJ has effects on  
121 exercise performance in the field.

122 We hypothesized that performing physical exercise at high altitude would increase tissue utilization  
123 of nitrate and nitrite as a result of the combination of metabolic (working muscle) and environmental  
124 (hypobaric) hypoxia, and that dietary nitrate supplementation could reverse this phenomenon by  
125 altering key determinants of aerobic exercise performance (particularly exercise efficiency – i.e. the  
126 ratio of mechanical work to energy expenditure during exercise) during sustained exposure to  
127 terrestrial high altitude.

128

## 129 **2 Methods**

## 130 **2.1 Participants:**

131 Twenty seven healthy volunteers completed the study (21 male; age, 28.9 ( $\pm$ 5.2) years; stature, 177  
132 ( $\pm$ 8) cm; body mass, 74.0 ( $\pm$ 11.3) kg;  $\dot{V}O_2$ peak at sea level (SL), 51.9 ( $\pm$ 9.9) ml/min/kg). Of the total  
133 sample, 21 (78%) had previously been to high altitude (>3,000 m), though nobody within the  
134 previous three months. For logistical reasons, participants were separated into two groups (A and B),  
135 according to their availability. Participants in both groups underwent sea level (SL) testing over two  
136 weekends (again, allocation to testing weekend was according to availability) and, approximately one  
137 month later, groups A and B ascended to the Margherita Hut (4559 m, high altitude or HA) one week  
138 apart. The study received institutional ethical approval from University College London and the  
139 University of Turin. Prior to enrolment, all participants provided written informed consent and  
140 successfully completed a health screening process detailed previously (38).

141

## 142 **2.2 Setting and ascent profile:**

143 Baseline measurements were taken in London, England (75 m, day 0). Participants began the  
144 expedition by flying to Milan (102 m) where they stayed overnight. The following day, they travelled  
145 by road, ski lifts and on foot to the Gnifetti Hut (3611 m). From this point, groups A and B had  
146 different ascent profiles due to a forecast of severe weather in the region altering Group A's ascent  
147 profile. After two days at Gnifetti Hut, Group A ascended by foot to the Margherita Hut (4559 m)  
148 where they stayed for testing for the remaining 8 days of the study. Group B stayed at the Gnifetti  
149 Hut for the scheduled three days, before trekking to the Margherita Hut, where they remained for 7  
150 days. Testing began after 5 days of being at high altitude (HA) and continued for 3 days, designated  
151 as days 1, 2 and 3 in **Supplementary Figure 1**. To maintain an equivalent hypoxic 'dose' within  
152 each group, participants remained within 300 vertical metres of the altitude of their overnight  
153 residence on non-ascent days.

154

## 155 **2.3 Intervention:**

156 This study used a randomized, double-blind, placebo-controlled factorial design, which has  
157 previously been described in full (38). Briefly, participants ingested either a beetroot/fruit juice  
158 beverage with high levels of nitrate (18.5 ( $\pm$ 2.0) mmol) (BRJ) or a nitrate-depleted beetroot/fruit

159 juice placebo (1.4 ( $\pm$ 0.1) mmol) (PLA) control drink (produced and provided by Aurapa GmbH,  
160 Bietigheim-Bissingen, Germany). Participants consumed the supplement each day in three 200 ml  
161 doses, resulting in a daily nitrate consumption of  $\sim$ 0.18 mmol/kg/day and  $\sim$ 11.5  $\mu$ moles/kg/day in the  
162 BRJ and PLA groups, respectively. Supplementation commenced three days prior to the exercise  
163 trials and continued throughout the testing period (see **Supplementary Figure 1**). During the study,  
164 food samples were taken from each meal and analysed for their nitrate and nitrite content. The  
165 average daily consumption of nitrate and nitrite from meals was consistent with normal UK daily  
166 intake (European Food Safety Authority, 2008), with nitrate and nitrite intakes of 18 ( $\pm$ 11)  
167  $\mu$ moles/kg/day and 0.038 ( $\pm$ 0.023)  $\mu$ moles/kg/day, respectively (39). As reported previously, plasma  
168 nitrate concentration was approximately 4-fold higher in the nitrate supplementation group,  
169 compared to placebo (regression coefficient (95% CI); 1.5 (1.3, 1.7),  $P < 0.001$ ) and remained  
170 elevated throughout the duration of the exercise testing period both at sea level and at altitude (see  
171 **Supplementary Table 1**) (40). Inter-day variability in baseline circulating nitrate and nitrite  
172 concentrations was minimal in both groups as reported previously, enabling exercise testing to be  
173 performed over consecutive days at altitude (it was impossible to test all participants in such a large  
174 group on one single day due to time and logistical constraints) (40).

175

## 176 **2.4 Exercise testing**

177 Participants underwent two exercise tests at SL and again at HA. The first test was a submaximal  
178 constant work rate test to determine exercise efficiency, and the second was a maximal exercise test  
179 investigating aerobic capacity. The tests were separated by at least 2 hours of rest to allow time for  
180 recovery. Participants wore a facemask for measurement of breath-by-breath pulmonary gas  
181 exchange (Metamax 3B, Cortex, Leipzig, Germany) and cycled on an electromagnetically braked  
182 cycle ergometer (Lode Corival, Lode, Groningen, Netherlands).

183 To determine exercise efficiency, participants cycled at three constant work rates (20, 40 and 60  
184 Watts) for 10 minutes each. The work rates were estimated to fall within the “moderate”-intensity  
185 exercise domain (i.e. below the ventilatory anaerobic threshold) to ensure estimates of efficiency  
186 were not affected by any increase in  $VO_2$  above AT (i.e. the  $VO_2$  slow component). Post hoc  
187 examination of ramp test data confirmed the work rates fell within the moderate intensity domain for  
188 all participants. Exercise efficiency was calculated from the final 5 minutes of expired air data from

189 each exercise stage using a 4-step process. Firstly, interpolation was used to transform breath-by-  
190 breath data to 20 second average data. Secondly, data was screened to ensure  $\dot{V}O_2$  did not increase  
191 more than 100 mls in the 5 min analysis window. This was the case for all tests. Thirdly, the mean  
192 value for  $\dot{V}O_2$  and  $\dot{V}CO_2$  were used to calculate energy expenditure using the equation of Brouwer  
193 (41). Finally, external work performed on the ergometer and energy expenditure results were used to  
194 calculate delta efficiency using linear regression.

195 A symptom-limited, incremental ramp cycling protocol to volitional exhaustion was performed at SL  
196 and HA by each participant to determine  $\dot{V}O_2$  peak and AT. The test began with 3 minutes of rest and  
197 a 3 minute 'unloaded' warm up, then participants performed the ramp section of the test to  
198 exhaustion. The work rate during the ramp increased by between 20 and 40 Watts each minute,  
199 depending on the fitness status of the participant and the altitude of the test.  $\dot{V}O_2$  peak was defined as  
200 the average of the highest exertional oxygen uptake achieved over the last 20 seconds of exercise.  
201 The AT was determined using the modified V-slope method (42), confirmed by patterns of change in  
202 ventilatory equivalent and end-tidal gas measurements (43). Each test was independently analyzed by  
203 two assessors (authors: PJH and AFO'D), each trained and experienced in AT determination. When  
204 assessors selected an AT with a difference of less than 5%, the value selected for subsequent analysis  
205 was agreed through discussion (n = 51). For cases where assessors 1 and 2 disagreed by more than  
206 5% (n=3 tests), a third opinion was sought (author: DZHL) to resolve the discrepancy (n=3). This  
207 method of AT determination has been previously validated against arterial lactate threshold values  
208 measured at high altitude (Levett et al., unpublished data). In addition to expired air gas analysis,  
209 continuous heart rate measurements were made, blood pressure was taken every 3 minutes, and a 3-  
210 lead ECG was continuously monitored (Multilyser, Cortex, Leipzig, Germany).

## 211 **2.5 Plasma collection and biomarker analysis**

212 Full methods for plasma sampling and analysis have previously been detailed elsewhere (40).  
213 Briefly, fasted venous blood samples (5 ml) were collected first thing in the morning at SL and on the  
214 1st, 3rd and 5th testing mornings (D1, D3 & D5) during the study at HA, using EDTA-containing BD  
215 Vacutainer™ tubes. Samples were also collected at 5 time points during the submaximal constant  
216 work rate exercise tests (E1 – 5); at the beginning of the test (E1), two minutes before the end of the  
217 20 W, 40 W & 60 W stages (E2, E3 and E4 respectively) and immediately before finishing the test  
218 during unloaded recovery (E5), see **Figure 1**. Every sample was centrifuged at 800 x g for 15 min



219 immediately after collection, aliquoted into separate cryovials and frozen ( $-40\text{ }^{\circ}\text{C}$  at the mountain  
220 and during transport, then  $-80\text{ }^{\circ}\text{C}$  until analysis).

221 All plasma biomarker concentrations were quantified after reaction with an excess of N-  
222 ethylmaleimide (10 mM NEM, in 10 mM phosphate buffered saline) added immediately after frozen  
223 plasma aliquots were thawed. To quantify plasma nitrite and nitrate concentrations, NEM-treated  
224 samples were deproteinized with methanol (1:1) and centrifuged at  $16,100 \times g$  for 10 min before  
225 undergoing analysis by high-pressure liquid chromatography (HPLC) using a dedicated nitrite/nitrate  
226 analyzer (ENO20, Eicom). All sample analysis was performed with repeated daily calibrations and  
227 staggered to ensure processing times were consistent, and all reported values were corrected for  
228 background levels of nitrite/nitrate. Nitroso product concentrations were quantified by group-specific  
229 denitrosation of NEM-treated EDTA plasma samples after injecting samples incubated with acidic  
230 sulfanilamide directly into an acidic triiodide-containing reaction chamber and measuring the NO  
231 liberated following reductive cleavage of protein nitroso-species by gas phase chemiluminescence  
232 (CLD 77am sp, EcoPhysics) as described (44).

233

## 234 **2.6 Data and statistical analysis:**

235 It was calculated that a sample size of 14 participants in each group would provide sufficient  
236 statistical power ( $0.8$ ;  $\beta = 0.20$ ) to detect a 10% difference in exercise efficiency during exercise from  
237 SL to HA using an alpha level of 0.05 (StatMate2, Graphpad software, San Diego, CA). These  
238 calculations were based on exercise efficiency being approximately  $22.3 (\pm 1.8)\%$  at sea level in  
239 healthy volunteers (11) and beetroot juice improving a related variable,  $\text{O}_2$  cost of exercise at sea  
240 level, by 7.1% (45). We expected greater improvement in exercise efficiency in hypoxia due to a  
241 more active nitrate–nitrite–NO reduction pathway and thus opted to power the study to detect at 10%  
242 difference. Initially, 28 participants (14 in each group) were recruited, but one individual was unable  
243 to complete testing at high altitude due to altitude related sickness (detailed in (38,39)), leaving data  
244 from 27 participants available for analysis.

245 Linear mixed modelling was used to analyse data to account for repeated measures and the different  
246 ascent profiles of each trek group (STATA 11, <http://www.stata.com>). All possible main effects and  
247 interactions of each outcome variable were compared across the two experimental groups, two  
248 altitudes, and two trek group ascent profiles. The interaction between the various independent

249 variables did not improve the fit of any of the models and therefore were not presented. Coefficients  
250 and p values are provided for; the treatment effect in response to taking the high nitrate dietary  
251 supplement, the effect of altitude, and the effect of the different trekking group ascent profile.  
252 Normally distributed data are presented as mean and 95% confidence intervals (CIs) and non-  
253 normally distributed data as median and inter-quartile (IQ) range. P values < 0.05 were considered  
254 significant.

255

## 256 **3 Results**

### 257 **3.1 Exercise efficiency**

258 Delta exercise efficiency was not altered by altitude exposure or by nitrate supplementation (**Table**  
259 **1**). Additionally, no interaction effect was present between altitude and nitrate supplementation.

### 260 **3.2 $\dot{V}O_{2peak}$ and anaerobic threshold**

261  $\dot{V}O_{2peak}$  decreased by 24% for the whole group at HA ( $P < 0.001$ ) (**Table 1**).  $\dot{V}O_{2peak}$  was lower in  
262 the group supplemented with dietary nitrate at both SL and HA compared to the placebo group ( $p =$   
263  $0.041$ ) (**Table 1**). However, no interaction effect was present between high altitude and nitrate  
264 supplementation.

265 Other peak exercise variables changed in response to altitude for the whole group; maximum work  
266 rate was reduced by 18% ( $p = 0.041$ ), maximum heart rate was lowered by 11% ( $p = 0.041$ ), and  
267 peak minute ventilation ( $\dot{V}_e$ ) was increased by 21% ( $p = 0.041$ ) (**Table 1**). Dietary nitrate  
268 supplementation did not significantly alter the peak values of these physiological variables (**Table 1**).

269 Oxygen consumption at AT was also lower at HA (23%), when compared to SL ( $p < 0.001$ ), but was  
270 not altered by nitrate supplementation ( $p = 0.431$ ) (**Table 1**).

271

### 272 **3.3 Plasma biomarkers**

273 At the time of exercise testing, circulating nitrate concentrations in individuals of the nitrate-  
274 supplemented group revealed a greater variability at SL compared to high altitude. We did not  
275 observe any significant change in nitrate, nitrite or nitroso product concentrations during the exercise

276 efficiency tests, neither at SL nor at HA (see **Figure 2** and **Supplementary Table 2**). In some  
277 individuals, circulating nitrite and nitroso product (particularly S-nitrosothiol) concentrations rose  
278 abruptly right after cessation of exercise in the efficiency testing protocol (timepoint E5 in **Figure 2**).

279

## 280 **4 Discussion**

### 281 **4.1 Main findings**

282 Our finding that nitrate supplementation did not alter exercise efficiency at HA should be viewed in  
283 the context of a conflicting body of literature indicating that, following supplementation, submaximal  
284 oxygen utilisation may either improve (22–24,26,27) or remain unchanged (25,29,31,34) under  
285 hypoxic conditions. Furthermore, neither AT, peak work rate, heart rate, nor ventilation were affected  
286 by nitrate supplementation. Meanwhile,  $\dot{V}O_{2peak}$  was lower following nitrate supplementation at SL  
287 and HA which supports some previous literature for hypoxic exposures at sea level (26), but  
288 contradicts others (30,31), though no interaction effect was present between altitude and nitrate  
289 supplementation. Overall, these findings suggest that supplementary nitrate is largely ineffective at  
290 altering exercise physiological responses to terrestrial high altitude.

291 No single variable appears to account for these conflicting results; with similar participant  
292 demographics, exercise test modalities and intensities revealing both positive and no effects of BRJ  
293 on exercise physiological responses to hypoxia. The lack of apparent effect cannot be attributed to  
294 ineffective supplementation either, as all studies that measured plasma nitrate and nitrite  
295 concentration found them to be elevated, irrespective of the study outcome (22–27,29,31,34).

296 In this study, plasma nitrate was 4-fold higher in the nitrate supplementation group (regression  
297 coefficient (95% CI); 1.5 (1.3, 1.7),  $P < 0.001$ ) (40), yet increasing work rate did not significantly  
298 alter plasma concentrations of nitrite, nitrate or nitroso species. Although, plasma nitrite and nitroso  
299 species did increase in a number of cases (often but not universally in the supplemented group)  
300 immediately after exercise ceased. This phenomenon may be related to the utilization of nitrite and  
301 nitroso species during exercise. Conceivably, ongoing sequential conversion of nitrate to nitrite and  
302 nitrite to nitroso products and NO in skeletal muscle can give rise to increased translocation of  
303 intermediary products from muscle to the systemic circulation upon abrupt cessation of the metabolic  
304 hypoxic stimulus. Translocation of nitrite and nitroso species may be triggered by the sudden change

305 in oxygen supply and demand as contractile activity stops. Little is known about the utilization of  
306 nitroso products during exercise, but the conversion of nitrite to nitroso species and NO (by various  
307 distinct mechanisms) is facilitated in hypoxia (16) and oxygen inhibits metabolic conversion of  
308 nitrite to NO (46). Thus, the rapid elevation of tissue oxygen availability in muscle may act as a  
309 break on both the downstream utilization of nitroso products and nitrite to NO reduction, with  
310 subsequent release of accumulating nitrite and nitroso species into lymph and blood. Why this  
311 process should occur faster in some individuals than others is not immediately obvious and warrants  
312 further investigation.

313 Skeletal muscle represents a quantitatively significant site of nitrate storage (47), and its uptake from  
314 the circulation is complex (48,49). Nitrate has been proposed to act as a regulator of systemic NO  
315 homeostasis by conversion into other NO-related species (50) and may thereby confer protection  
316 against tissue damage. NO plays a key role in enabling oxygen and nutrient delivery by improving  
317 blood flow, and also in matching energy supply with demand by modulating mitochondrial function  
318 and intermediary metabolism (9). The variability in quality and magnitude of the nitrite and  
319 nitrosothiol accumulation observed after cessation of exercise suggests differences in metabolic  
320 fluxes exist between individuals, however the significance of this observation is currently unclear and  
321 warrants further investigation. Stable-isotope labelled nitrate studies could characterize the role of  
322 individual nitrate-related metabolites in these pathways.

323 The lack of differences observed for most variables in this study could be related to the  
324 supplementation regime. In most previous studies, a single high dose (bolus) of nitrate (~6-13  
325 mmoles) was consumed 2-3 hours prior to the exercise trial (22–24,26,29,31,32,34). Whereas, our  
326 ~8.5 mmol daily dose was split into 3 equal parts consumed throughout the day, designed to produce  
327 a sustained elevation in plasma nitrate. Consuming a single high dose (8.4 mmol) of nitrate increases  
328 plasma nitrate to ~300  $\mu\text{M}$  after 2 hours (51), whereas average plasma nitrate concentration in the  
329 intervention group of the current study was ~85  $\mu\text{M}$ . As we have discussed previously, these lower  
330 plasma nitrate values may also reflect a hypoxia-mediated loss of plasma nitrate due to increased  
331 nitrate utilization, uptake by other tissues, or elimination from the body (40). Such changes would be  
332 unlikely to occur during very short-lived hypoxic exposures, possibly explaining the higher plasma  
333 nitrate values observed in acute studies. Circulating plasma nitrate levels correlate with administered  
334 dose (51). If peak nitrate concentrations, rather than its sustained elevation over time, drives nitrate  
335 induced physiological changes then this may explain why differences were not observed here.

336 Despite a significant elevation of circulating nitrite at Day 5, circulating nitrite concentrations were  
337 not significantly different from those in the placebo group on all other days, see **Supplementary**  
338 **Table 1** (40). If nitrite (rather than nitrate) is the driver for alterations in exercise physiology, then  
339 this is the most likely explanation for why no such changes were observed in this study.

340 However, nitrate supplementation was not ineffective overall. Besides the elevation in exhaled NO  
341 reported previously (39), one variable that was clearly altered by nitrate supplementation in the  
342 present study was  $\dot{V}O_{2peak}$ , which was lower in the treatment group at both SL and HA. A nitrate-  
343 induced reduction in  $\dot{V}O_{2peak}$  has previously been reported at SL (45,52) and in hypoxia (26),  
344 though conflicting evidence also exists (27,30,53). As no interaction was found between  
345 supplementation and altitude, either; a) nitrate reduced  $\dot{V}O_{2peak}$  at SL and that this reduction was  
346 sustained whilst at altitude, or b) the random allocation of participants within the groups meant that  
347 this difference at sea level was a random error. The reduced  $\dot{V}O_{2peak}$  may be a reflection of  
348 alteration in electron flow within the mitochondrial respiratory chain but is unlikely to confer an  
349 advantage for exercise performance, except for possibly preventing tissue damage due to enhanced  
350 reactive oxygen species production at higher work rates. As this is the first study to investigate the  
351 effect of BRJ on  $\dot{V}O_{2peak}$  over this duration of altitude exposure, further study is warranted,  
352 particularly as no pre-supplementation measures were taken to rule out bias caused by potential  
353 issues of imperfect randomization of a relatively small sample.

354 Whilst similarities exist between the current study and previous literature on this topic, our results  
355 stand alone in that, for the first time, they show supplementary nitrate is not an effective ergogenic  
356 aid during prolonged periods (8 days) at terrestrial altitude. This may indicate that the potential  
357 benefits of supplementary nitrate on exercise outcomes some studies report are limited to acute  
358 hypoxia at sea level (22–24,26,27). Previous results from this expedition also found nitrate was  
359 ineffective at altering resting respiratory function, blood pressure (39), and microcirculatory flow  
360 (40), and results from an earlier expedition indicated that BRJ also did not alter acute mountain  
361 sickness or basic physiological responses during an 11 day high altitude trek (2). In contrast, acute  
362 BRJ supplementation has been reported to normalize brachial flow-mediated dilation after 7-8 days  
363 of high altitude, but was without effect on other physiological responses such as arterial oxygen  
364 saturation, vascular function and arterial blood pressure (54). As hypoxia is typically experienced  
365 over prolonged periods, together, these results question whether nitrate supplementation has any

366 practical utility at high altitude. However, in the absence of large numbers of studies conducted over  
367 this time frame the role of the supplement over this longer period is still largely unknown.

368

## 369 **4.2 Strengths and Limitations**

370 This is the first investigation to study the effect of BRJ supplementation on exercise physiological  
371 responses during prolonged exposure to terrestrial altitude. This use of terrestrial altitude, rather than  
372 normobaric hypoxia, is important as physiological responses may differ between the two (37).  
373 Furthermore, investigating the effectiveness of BRJ over multiple days at terrestrial high altitude  
374 more closely mimics how most people experience hypoxia and thus results are more ecologically  
375 valid. The current study suffers from a number of limitations related to study design. Firstly, we used  
376 case-control rather than cross-over research design which introduces between-subject variation. The  
377 duration of altitude exposure precluded a cross-over design without including a prolonged (several  
378 months) ‘wash-out’ period between two identical treks, which was not feasible. The increase in  
379 variability was combated by employing a sufficiently large sample size based on power calculations.  
380 Secondly, initial testing was preceded by 3 days of BRJ supplementation which precluded pre-  
381 supplementation testing without implementing an additional day of testing which was not possible  
382 due to time and logistical restraints. The omission of pre-supplementation measurements made it  
383 impossible to investigate whether variation in the physiological responses to BRJ ingestion could be  
384 attributed to differences in individuals’ capacity to increase circulating nitrate/nitrite, as has been  
385 previously suggested (55). Finally, plasma nitrate concentrations provide a reserve for NO synthesis,  
386 the increases in plasma nitrate with BRJ that we observed were lower than acute studies that showed  
387 improvements in exercise variables in acute hypoxic environments. As such, much larger nitrate  
388 doses may be required to elicit beneficial effects on exercise variables at terrestrial altitude. Lastly,  
389 we cannot exclude that other biologically active BRJ constituents (56) may have had confounding  
390 effects as they could have affected skeletal muscle physiology in the placebo group.

391

## 392 **5 Conclusion**

393 This study indicates that, whilst consumed during an 8 day expedition to terrestrial high altitude,  
394 nitrate supplementation did not alter exercise efficiency. Furthermore, AT, peak work rate, heart rate,

395 and ventilation were not affected by nitrate supplementation.  $\dot{V}O_{2peak}$  was lower in the group  
396 supplemented with dietary nitrate at both SL and high altitude. The results of this study and others  
397 question the practical utility of supplementing with BRJ during prolonged altitude exposure.  
398 However, this study is the first to investigate the role of BRJ on exercise physiological outcomes  
399 over a sustained exposure to terrestrial altitude, and thus further research is required before making  
400 definitive conclusions.

401

## 402 **Acknowledgements**

403 The Xtreme Alps research group members all contributed to the data collection for this study. The  
404 group consists of: Tom Adams, Lindsay Bisiker, Adam Booth, Oliver Burdall, Alexandra Cobb,  
405 Andrew Cumpstey, Steve Dauncey, Mark Edsell, James Farrant, Martin Feelisch, Bernadette  
406 Fernandez, Oliver Firth, Edward Gilbert, Daniel Grant, Michael Grocott, Phil Hennis, Laura Jackson,  
407 Will Jenner, Jildou van der Kaaij, Maryam Khosravi, Edith Kortekaas, Denny Levett, Zeyn  
408 Mahomed, Daniel Martin, Paula Meale, Jim Milledge, Kay Mitchell, Damian Mole, Oliver Moses,  
409 Michael Mythen, Fabio Rigat, Alasdair O'Doherty, Alex Salam, Matt Sanborn, Adam Sheperdigian,  
410 Fiona Shrubbs, Jo Simpson, Nick Talbot, Liesl Wandrag, Savini Wijesingha, Wilby Williamson, Tom  
411 Woolley, Heng Yow.

412 We are grateful for early statistical advice from Vassiliki Bountziouka (University College London)  
413 and expert statistical support and advice from Borislav Dimitriov (University of Southampton  
414 Biomedical Research Centre). Further thanks go to Tobias Pöhl for his help with processing,  
415 pasteurising and packaging the juice supplement drinks.

## 416 **Author Contributions**

417 Conception of study: HP, MGM, MPWG, DZHL, DSM, MF

418 Data collection: PJH, AOD, KM, AC, PM, BOF

419 Data analysis: PJH, AFC, AOD, BOF, HM,

420 Writing of manuscript: PJH, AFC, MF,

421 Editing of manuscript: PJH, AFC, MPWG, DZHL, DSM, MF, AOD

422 Final approval of manuscript: All authors

423 **Funding**

424 Xtreme Alps received charitable support from the Friends of University College Hospital NHS  
425 Foundation Trust as well as unrestricted research funding from Smiths Medical Ltd. and Deltex  
426 Medical Ltd. MP, LH and MF acknowledge support from the Faculty of Medicine, University of  
427 Southampton. Part of the work carried out at the University of Warwick was supported by funds from  
428 the Medical Research Council (Strategic Appointment Scheme, to MF). None of the funding bodies  
429 or the institutions the authors are affiliated with had any role in the study design; collection, analysis,  
430 and interpretation of data; manuscript preparation, or decision to publish. AFC is funded by the  
431 National Institute for Health Research Southampton Biomedical Research Centre and has also  
432 received funding as a National Institute for Health Research Academic Clinical Fellow. KM is a  
433 National Institute for Health Research (NIHR) Senior Nurse and Midwife Research Leader. The  
434 views expressed in this article are those of the author and not necessarily those of the NIHR or of the  
435 Department of Health & Social Care.

436

437 **Conflicts of Interest**

438 This study received funding from Smiths Medical Ltd and Deltex Medical Ltd. These funders were  
439 not involved in the study design, collection, analysis, interpretation of data, the writing of this article  
440 or the decision to submit it for publication. MPWG serves on the medical advisory board of Sphere  
441 Medical Ltd and is a director of Oxygen Control Systems Ltd. He has received honoraria for  
442 speaking for and/or travel expenses from BOC Medical (Linde Group), Edwards Lifesciences and  
443 Cortex GmbH. MPWG leads the Xtreme- Everest Oxygen Research Consortium and the Fit-4-  
444 Surgery research collaboration. MPWG serves as the UK NIHR CRN national specialty group lead  
445 for Anaesthesia Perioperative Medicine and Pain and is an elected council member of the Royal  
446 College of Anaesthetists. DM has received lecture and consultancy fees from Siemens Healthineers  
447 and Edwards LifeSciences. MGM is a paid Consultant for Edwards Lifesciences; his University  
448 Chair is sponsored by Smiths Medical; he is the founding Editor of the Journal Perioperative  
449 Medicine and sits on the Editorial Board of the British Journal of Anaesthesia; he is the Editor-in-  
450 Chief of TopMedTalk. All other authors have no competing interests to declare.



452 **References**

- 453 1. Griva K, Stygall J, Wilson MH, Martin D, Levett D, Mitchell K, et al. Caudwell Xtreme  
454 Everest: A prospective study of the effects of environmental hypoxia on cognitive functioning.  
455 PLOS ONE. 2017 Mar 27;12(3):e0174277.
- 456 2. Hennis PJ, Mitchell K, Gilbert-Kawai E, Bountziouka V, Wade A, Feelisch M, et al. Effects of  
457 dietary nitrate supplementation on symptoms of acute mountain sickness and basic  
458 physiological responses in a group of male adolescents during ascent to Mount Everest Base  
459 Camp. Nitric Oxide. 2016 Nov 30;60:24–31.
- 460 3. Roach RC, Maes D, Sandoval D, Robergs RA, Icenogle M, Hinghofer-Szalkay H, et al.  
461 Exercise exacerbates acute mountain sickness at simulated high altitude. Journal of Applied  
462 Physiology. 2000 Feb 1;88(2):581–5.
- 463 4. Taylor AT. High-Altitude Illnesses: Physiology, Risk Factors, Prevention, and Treatment.  
464 Rambam Maimonides Med J. 2011 Jan 31;2(1):e0022.
- 465 5. Beall CM, Laskowski D, Erzurum SC. Nitric oxide in adaptation to altitude. Free Radical  
466 Biology and Medicine. 2012 Apr 1;52(7):1123–34.
- 467 6. Luks AM, Levett D, Martin DS, Goss CH, Mitchell K, Fernandez BO, et al. Changes in acute  
468 pulmonary vascular responsiveness to hypoxia during a progressive ascent to high altitude  
469 (5300 m). Exp Physiol. 2017 Jun 1;102(6):711–24.
- 470 7. Siervo M, Riley HL, Fernandez BO, Leckstrom CA, Martin DS, Mitchell K, et al. Effects of  
471 prolonged exposure to hypobaric hypoxia on oxidative stress, inflammation and gluco-insular  
472 regulation: the not-so-sweet price for good regulation. PLoS ONE. 2014;9(4):e94915.
- 473 8. Murray AJ, Montgomery HE, Feelisch M, Grocott MPW, Martin DS. Metabolic adjustment to  
474 high-altitude hypoxia: from genetic signals to physiological implications. Biochem Soc Trans.  
475 2018 Apr 20;
- 476 9. Umbrello M, Dyson A, Feelisch M, Singer M. The Key Role of Nitric Oxide in Hypoxia:  
477 Hypoxic Vasodilation and Energy Supply–Demand Matching. Antioxidants & Redox Signaling.  
478 2013 Jan 11;19(14):1690–710.
- 479 10. Erzurum SC, Ghosh S, Janocha AJ, Xu W, Bauer S, Bryan NS, et al. Higher blood flow and  
480 circulating NO products offset high-altitude hypoxia among Tibetans. Proc Natl Acad Sci U S  
481 A. 2007 Nov 6;104(45):17593–8.
- 482 11. Levett DZ, Fernandez BO, Riley HL, Martin DS, Mitchell K, Leckstrom CA, et al. The role of  
483 nitrogen oxides in human adaptation to hypoxia. Scientific Reports. 2011 Oct 6;1(109).
- 484 12. Janocha AJ, Koch CD, Tiso M, Ponchia A, Doctor A, Gibbons L, et al. Nitric Oxide during  
485 Altitude Acclimatization. New England Journal of Medicine. 2011 Nov 17;365(20):1942–4.

- 486 13. Feelisch M. Enhanced nitric oxide production is a universal response to hypoxic stress. *National*  
487 *Science Review*. 2018 Jul 1;5(4):532–3.
- 488 14. Butler AR, Feelisch M. Therapeutic Uses of Inorganic Nitrite and Nitrate. *Circulation*. 2008 Apr  
489 22;117(16):2151–9.
- 490 15. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology  
491 and therapeutics. *Nat Rev Drug Discov*. 2008 Feb;7(2):156–67.
- 492 16. Lundberg JO, Gladwin MT, Ahluwalia A, Benjamin N, Bryan NS, Butler A, et al. Nitrate and  
493 nitrite in biology, nutrition and therapeutics. *Nat Chem Biol*. 2009 Dec;5(12):865–9.
- 494 17. Bahadoran Z, Mirmiran P, Kabir A, Azizi F, Ghasemi A. The Nitrate-Independent Blood  
495 Pressure–Lowering Effect of Beetroot Juice: A Systematic Review and Meta-Analysis. *Adv*  
496 *Nutr*. 2017 Nov 7;8(6):830–8.
- 497 18. McMahon NF, Leveritt MD, Pavey TG. The Effect of Dietary Nitrate Supplementation on  
498 Endurance Exercise Performance in Healthy Adults: A Systematic Review and Meta-Analysis.  
499 *Sports Med*. 2017 Apr;47(4):735–56.
- 500 19. Jones AM, Thompson C, Wylie LJ, Vanhatalo A. Dietary Nitrate and Physical Performance.  
501 *Annual Review of Nutrition*. 2018;38(1):303–28.
- 502 20. Olsson H, Al-Saadi J, Oehler D, Pergolizzi J, Magnusson P. Physiological Effects of Beetroot in  
503 Athletes and Patients. *Cureus*. 2019 Dec 11;11(12):e6355.
- 504 21. Jones AM, Vanhatalo A, Seals DR, Rossman MJ, Piknova B, Jonvik KL. Dietary Nitrate and  
505 Nitric Oxide Metabolism: Mouth, Circulation, Skeletal Muscle, and Exercise Performance. *Med*  
506 *Sci Sports Exerc*. 2021 Feb 1;53(2):280–94.
- 507 22. Shannon OM, Duckworth L, Barlow MJ, Woods D, Lara J, Siervo M, et al. Dietary nitrate  
508 supplementation enhances high-intensity running performance in moderate normobaric hypoxia,  
509 independent of aerobic fitness. *Nitric Oxide*. 2016 Sep 30;59:63–70.
- 510 23. Muggeridge DJ, Howe CCF, Spendiff O, Pedlar C, James PE, Easton C. A single dose of  
511 beetroot juice enhances cycling performance in simulated altitude. *Med Sci Sports Exerc*. 2014  
512 Jan;46(1):143–50.
- 513 24. Shannon OM, Duckworth L, Barlow MJ, Deighton K, Matu J, Williams EL, et al. Effects of  
514 Dietary Nitrate Supplementation on Physiological Responses, Cognitive Function, and Exercise  
515 Performance at Moderate and Very-High Simulated Altitude. *Front Physiol*. 2017 Jun 9;8.
- 516 25. Horiuchi M, Endo J, Dobashi S, Handa Y, Kiuchi M, Koyama K. Muscle oxygenation profiles  
517 between active and inactive muscles with nitrate supplementation under hypoxic exercise.  
518 *Physiological Reports*. 2017;5(20):e13475.
- 519 26. Kelly J, Vanhatalo A, Bailey SJ, Wylie LJ, Tucker C, List S, et al. Dietary nitrate  
520 supplementation: effects on plasma nitrite and pulmonary O<sub>2</sub> uptake dynamics during exercise  
521 in hypoxia and normoxia. *American Journal of Physiology - Regulatory, Integrative and*  
522 *Comparative Physiology*. 2014 Oct 1;307(7):R920–30.

- 523 27. Masschelein E, Thienen RV, Wang X, Schepdael AV, Thomis M, Hespel P. Dietary nitrate  
524 improves muscle but not cerebral oxygenation status during exercise in hypoxia. *Journal of*  
525 *Applied Physiology*. 2012 Sep 1;113(5):736–45.
- 526 28. Vanhatalo A, Fulford J, Bailey SJ, Blackwell JR, Winyard PG, Jones AM. Dietary nitrate  
527 reduces muscle metabolic perturbation and improves exercise tolerance in hypoxia. *The Journal*  
528 *of Physiology*. 2011;589(22):5517–28.
- 529 29. MacLeod KE, Nugent SF, Barr SI, Koehle MS, Sporer BC, MacInnis MJ. Acute Beetroot Juice  
530 Supplementation Does Not Improve Cycling Performance in Normoxia or Moderate Hypoxia.  
531 *International Journal of Sport Nutrition and Exercise Metabolism*. 2015 Aug 1;25(4):359–66.
- 532 30. Arnold JT, Oliver SJ, Lewis-Jones TM, Wylie LJ, Macdonald JH. Beetroot juice does not  
533 enhance altitude running performance in well-trained athletes. *Appl Physiol Nutr Metab*. 2015  
534 Jun 1;40(6):590–5.
- 535 31. Nybäck L, Glännerud C, Larsson G, Weitzberg E, Shannon OM, McGawley K. Physiological  
536 and performance effects of nitrate supplementation during roller-skiing in normoxia and  
537 normobaric hypoxia. *Nitric Oxide [Internet]*. 2017 Aug 4 [cited 2017 Aug 14]; Available from:  
538 <http://www.sciencedirect.com/science/article/pii/S1089860317300885>
- 539 32. Carriker C.R., Mermier C.M., Van Dusseldorp T.A., Johnson K.E., Beltz N.M., Vaughan R.A.,  
540 et al. Effect of acute dietary nitrate consumption on oxygen consumption during submaximal  
541 exercise in hypobaric hypoxia. *Int J Sport Nutr Exer Metabol*. 2016;26(4):315–22.
- 542 33. Gasier HG, Reinhold AR, Loiselle AR, Soutiere SE, Fothergill DM. Effects of oral sodium  
543 nitrate on forearm blood flow, oxygenation and exercise performance during acute exposure to  
544 hypobaric hypoxia (4300 m). *Nitric Oxide*. 2017 Sep 30;69:1–9.
- 545 34. Rossetti GMK, Macdonald JH, Wylie LJ, Little SJ, Newton V, Wood B, et al. Dietary nitrate  
546 supplementation increases acute mountain sickness severity and sense of effort during hypoxic  
547 exercise. *Journal of Applied Physiology*. 2017 Jul 6;123(4):983–92.
- 548 35. Jones AM, Wilkerson DP, Vanhatalo A, Burnley M. Influence of pacing strategy on O<sub>2</sub> uptake  
549 and exercise tolerance. *Scandinavian Journal of Medicine & Science in Sports*. 2008;18(5):615–  
550 26.
- 551 36. Affourtit C, Bailey SJ, Jones AM, Smallwood MJ, Winyard PG. On the mechanism by which  
552 dietary nitrate improves human skeletal muscle function. *Front Physiol*. 2015;6:211.
- 553 37. Coppel J, Hennis P, Gilbert-Kawai E, Grocott MP. The physiological effects of hypobaric  
554 hypoxia versus normobaric hypoxia: a systematic review of crossover trials. *Extreme*  
555 *Physiology & Medicine*. 2015 Feb 26;4(1):2.
- 556 38. Martin DS, Gilbert-Kawai ET, Meale PM, Fernandez BO, Cobb A, Khosravi M, et al. Design  
557 and conduct of ‘Xtreme Alps’: A double-blind, randomised controlled study of the effects of  
558 dietary nitrate supplementation on acclimatisation to high altitude. *Contemporary Clinical*  
559 *Trials*. 2013 Nov 1;36(2):450–9.


- 560 39. Cumpstey AF, Hennis PJ, Gilbert-Kawai ET, Fernandez BO, Poudevigne M, Cobb A, et al.  
561 Effects of dietary nitrate on respiratory physiology at high altitude - Results from the Xtreme  
562 Alps study. *Nitric Oxide*. 2017 Dec 1;71(Supplement C):57–68.
- 563 40. Cumpstey AF, Hennis PJ, Gilbert-Kawai ET, Fernandez BO, Grant D, Jenner W, et al. Effects  
564 of dietary nitrate supplementation on microvascular physiology at 4559 m altitude – A  
565 randomised controlled trial (Xtreme Alps). *Nitric Oxide*. 2020 Jan 1;94:27–35.
- 566 41. Brouwer E. On simple formulae for calculating the heat expenditure and the quantities of  
567 carbohydrate and fat oxidized in metabolism of men and animals, from gaseous exchange  
568 (Oxygen intake and carbonic acid output) and urine-N. *Acta Physiol Pharmacol Neerl*.  
569 1957;6:795–802.
- 570 42. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas  
571 exchange. *J Appl Physiol* (1985). 1986 Jun;60(6):2020–7.
- 572 43. Whipp BJ, Ward SA, Wasserman K. Respiratory markers of the anaerobic threshold. *Adv*  
573 *Cardiol*. 1986;35:47–64.
- 574 44. Feelisch M, Rassaf T, Mnaimneh S, Singh N, Bryan NS, Jourdain D, et al. Concomitant S-,  
575 N-, and heme-nitros(yl)ation in biological tissues and fluids: implications for the fate of NO in  
576 vivo. *FASEB J*. 2002 Jan 11;16(13):1775–85.
- 577 45. Larsen FJ, Weitzberg E, Lundberg JO, Eklom B. Effects of dietary nitrate on oxygen cost  
578 during exercise. *Acta Physiologica*. 2007 Sep 1;191(1):59–66.
- 579 46. Feelisch M, Fernandez BO, Bryan NS, Garcia-Saura MF, Bauer S, Whitlock DR, et al. Tissue  
580 processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging  
581 systems. *J Biol Chem*. 2008 Dec 5;283(49):33927–34.
- 582 47. Piknova B, Park JW, Swanson KM, Dey S, Noguchi CT, Schechter AN. Skeletal muscle as an  
583 endogenous nitrate reservoir. *Nitric Oxide*. 2015 May 1;47:10–6.
- 584 48. Gilliard CN, Lam JK, Cassel KS, Park JW, Schechter AN, Piknova B. Effect of dietary nitrate  
585 levels on nitrate fluxes in rat skeletal muscle and liver. *Nitric Oxide*. 2018 May 1;75:1–7.
- 586 49. Wylie LJ, Park JW, Vanhatalo A, Kadach S, Black MI, Stoyanov Z, et al. Human skeletal  
587 muscle nitrate store: influence of dietary nitrate supplementation and exercise. *J Physiol*. 2019  
588 Dec;597(23):5565–76.
- 589 50. Piknova B, Schechter AN, Park JW, Vanhatalo A, Jones AM. Skeletal Muscle Nitrate as a  
590 Regulator of Systemic Nitric Oxide Homeostasis. *Exerc Sport Sci Rev*. 2021 Oct 16;
- 591 51. Wylie LJ, Kelly J, Bailey SJ, Blackwell JR, Skiba PF, Winyard PG, et al. Beetroot juice and  
592 exercise: pharmacodynamic and dose-response relationships. *Journal of Applied Physiology*.  
593 2013 Aug 1;115(3):325–36.
- 594 52. Bescós R, Ferrer-Roca V, Galilea PA, Roig A, Drobnic F, Sureda A, et al. Sodium nitrate  
595 supplementation does not enhance performance of endurance athletes. *Med Sci Sports Exerc*.  
596 2012 Dec;44(12):2400–9.

- 597 53. Perez JM, Dobson JL, Ryan GA, Riggs AJ. The Effects of Beetroot Juice on VO<sub>2</sub>max and  
598 Blood Pressure during Submaximal Exercise. *Int J Exerc Sci.* 2019;12(2):332–42.
- 599 54. Bakker E, Engan H, Patrician A, Schagatay E, Karlsen T, Wisløff U, et al. Acute dietary nitrate  
600 supplementation improves arterial endothelial function at high altitude: A double-blinded  
601 randomized controlled cross over study. *Nitric Oxide.* 2015 Nov 15;50:58–64.
- 602 55. Wilkerson DP, Hayward GM, Bailey SJ, Vanhatalo A, Blackwell JR, Jones AM. Influence of  
603 acute dietary nitrate supplementation on 50 mile time trial performance in well-trained cyclists.  
604 *Eur J Appl Physiol.* 2012 Dec;112(12):4127–34.
- 605 56. Torrens C, Feelisch M. How to beet hypertension in pregnancy: is there more to beetroot juice  
606 than nitrate? *J Physiol.* 2020 Sep;598(18):3823–4.
- 607
- 608
- 609

610 **Table 1:** Descriptive results and regression coefficients for exercise physiological variables  
611 according to linear mixed modelling. SL = sea level, HA = high altitude,  $\dot{V}O_{2peak}$  = peak oxygen  
612 consumption,  $\dot{V}_e$  = minute ventilation,  $\dot{V}O_2$  = oxygen consumption, AT = ventilatory anaerobic  
613 threshold. Data are presented as mean ( $\pm$ SD) or median (IQR) as appropriate. \*Mixed effect multiple  
614 linear regression analysis conducted with log transformed data.

Altitude	Placebo	Treatment	Mixed model analysis	$\beta$	95% Conf. int.	P value
Delta Efficiency (%)						
SL	26.3 (2.4)	26.5 (3.0)	Experimental group	0.138	-1.17, 1.44	0.836
			Altitude	-1.20	-2.50, 0.108	0.072
HA	24.4 (2.2)	26.1 (2.6)	Trek group	0.832	22.5, 27.5	0.227
$\dot{V}O_{2peak}$ (ml/kg/min)						
SL	55.1 (8.4)	48.4 (10.5)	Experimental group	-5.90	-11.5, -0.227	0.041
			Altitude	-12.2	-14.2, -10.2	<0.001
HA	42.2 (6.5)	36.9 (8.0)	Trek group	3.14	-2.73, 9.00	0.295

Work rate max* (Watts)						
SL	328 (284, 336)	313 (224, 343)	Experimental group	-0.0783	-0.219, 0.0620	0.274
			Altitude	-0.200	-0.236, -0.166	<0.001
HA	261 (243, 313)	260 (224, 295)	Trek group	-0.052	-0.197, 0.0937	0.487
Heart rate max (beat per minute)						
SL	181 (9)	178 (10)	Experimental group	-2.57	-9.73, 4.59	0.482
			Altitude	-17.5	-23.1, 11.8	<0.001
HA	163 (12)	161 (16)	Trek group	3.51	-3.88, 10.9	0.352
$\dot{V}_e$ max (L/min)						
SL	126 (22)	109 (33)	Experimental group	-18.8	-38.1, 0.572	0.057
			Altitude	31.7	24.8, 38.7	<0.001
HA	159 (29)	139 (30)	Trek group	-4.42	-24.4, 15.6	0.665
$\dot{V}O_2$ at AT* (ml/kg/min)						
SL	27.5 (22.4, 31.2)	26.1 (23.0, 29.9)	Experimental group	-0.0672	-0.235, 0.100	0.431
			Altitude	-0.259	-0.325, -0.193	<0.001
HA	21.1 (18.1, 23.7)	21.4 (15.8, 24.8)	Trek group	0.0847	-0.0884, 0.258	0.338




616

617 **Figure 1:** Profile of submaximal constant **work rate** exercise tests (performed at both sea level and  
 618 high altitude) and the five time points where plasma was collected during these tests: the beginning  
 619 of the test (E1), two minutes before the end of the 20 W, 40 W & 60 W stages (E2, E3 and E4  
 620 respectively) and immediately before finishing the test during unloaded recovery (E5).

621

622

623 **Figure 2:** Quantification of plasma biomarkers collected at different timepoints during exercise  
 624 efficiency tests at both sea level (left hand panels) and high altitude (right hand panels) in participants  
 625 taking either the placebo (black data points) or high nitrate (blue data points) supplement. A = plasma  
 626 nitrite, B = plasma nitrate, C = plasma S-nitrosothiols (RSNO), D = plasma N-nitrosamines (RNNO)



627



